Name | Title | Contact Details |
---|---|---|
Maggi Gentle |
Vice President Human Resources | Profile |
Lori Lawley |
Chief Financial Officer | Profile |
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
BioExx Specialty Proteins Ltd. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Aragen Biosciences is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.
Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.